{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T07:12:21Z","timestamp":1715670741052},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40121-020-00293-7","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T13:03:42Z","timestamp":1586955822000},"page":"355-365","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of Elbasvir\/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection"],"prefix":"10.1007","volume":"9","author":[{"given":"Amy","family":"Puenpatom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashem B.","family":"El-Serag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"7","key":"293_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/cid\/civ1222","volume":"62","author":"S Saeed","year":"2016","unstructured":"Saeed S, Strumpf EC, Walmsley SL, Roolet-Kurhajec K, Pick N, Martel-Laferniere V, et al. How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world? Clin Infect Dis. 2016;62(7):919\u201326. https:\/\/doi.org\/10.1093\/cid\/civ1222.","journal-title":"Clin Infect Dis"},{"key":"293_CR2","unstructured":"Zepatier [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme, Corp., Inc.; 2018."},{"key":"293_CR3","unstructured":"Zepatier [summary of product characteristics]. Hoddesdon, Hertfordshire, UK: Merck Sharp & Dohme Ltd.; 2018."},{"issue":"10","key":"293_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/m15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(10):1\u201313. https:\/\/doi.org\/10.7326\/m15-0785.","journal-title":"Ann Intern Med."},{"issue":"1","key":"293_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","volume":"152","author":"P Kwo","year":"2017","unstructured":"Kwo P, Gane E, Peng CY, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164\u201375. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.045.","journal-title":"Gastroenterology."},{"issue":"10003","key":"293_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(15)00349-9.","journal-title":"Lancet"},{"issue":"8","key":"293_CR7","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319\u201327. https:\/\/doi.org\/10.1016\/S2352-3018(15)00114-9.","journal-title":"Lancet HIV."},{"issue":"3","key":"293_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/hep.29139","volume":"66","author":"C Hezode","year":"2017","unstructured":"Hezode C, Colombo M, Bourliere M, Spengler U, Ben-Ari Z, Strasser SI, et al. Elbasvir\/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology. 2017;66(3):736\u201345. https:\/\/doi.org\/10.1002\/hep.29139.","journal-title":"Hepatology"},{"issue":"6","key":"293_CR9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2017.01.050","volume":"152","author":"IM Jacobson","year":"2017","unstructured":"Jacobson IM, Lawitz E, Kwo PY, Hezode C, Peng CY, Howe AYM, et al. Safety and efficacy of elbasvir\/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017;152(6):1372\u20131382.e2. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.050.","journal-title":"Gastroenterology."},{"issue":"9","key":"293_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/liv.13727","volume":"38","author":"T Asselah","year":"2018","unstructured":"Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int. 2018;38(9):1583\u201391. https:\/\/doi.org\/10.1111\/liv.13727.","journal-title":"Liver Int."},{"issue":"11","key":"293_CR11","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/jvh.12937","volume":"25","author":"JR Kramer","year":"2018","unstructured":"Kramer JR, Puenpatom A, Erickson KF, Cao Y, Smith D, El-Serag HB, et al. Real-world effectiveness of elbasvir\/grazoprevir in HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018;25(11):1270\u20139. https:\/\/doi.org\/10.1111\/jvh.12937.","journal-title":"J Viral Hepat."},{"issue":"11","key":"293_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158(11):807\u201320. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00005.","journal-title":"Ann Intern Med"},{"key":"293_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"National Kidney Foundation","year":"2013","unstructured":"National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"293_CR14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","volume":"151","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131\u201340. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.004.","journal-title":"Gastroenterology"},{"issue":"4","key":"293_CR15","doi-asserted-by":"publisher","first-page":"e00007","DOI":"10.14309\/ctg.0000000000000007","volume":"10","author":"IM Jacobson","year":"2019","unstructured":"Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, et al. Elbasvir\/grazoprevir in people with hepatitis C genotype 1 infection and Child-Pugh class B cirrhosis: the C-SALT Study. Clin Transl Gastroenterol. 2019;10(4):e00007. https:\/\/doi.org\/10.14309\/ctg.0000000000000007.","journal-title":"Clin Transl Gastroenterol."},{"issue":"5","key":"293_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-018-1429-3","volume":"53","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018;53(5):679\u201388. https:\/\/doi.org\/10.1007\/s00535-018-1429-3.","journal-title":"J Gastroenterol"},{"issue":"10","key":"293_CR17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","unstructured":"AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477\u201392. https:\/\/doi.org\/10.1093\/cid\/ciy585.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"293_CR18","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s00535-018-1473-z","volume":"53","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, et al. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2018;53(12):1276\u201384. https:\/\/doi.org\/10.1007\/s00535-018-1473-z.","journal-title":"J Gastroenterol"},{"key":"293_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.antiviral.2018.10.003","volume":"159","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Furusyo N, Azuma K, Nakamuta M, Nomura H, Dohmen K, et al. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: a multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Res. 2018;159:143\u201352. https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.003.","journal-title":"Antiviral Res"},{"issue":"1","key":"293_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jvh.13008","volume":"26","author":"M Hernandez-Conde","year":"2019","unstructured":"Hernandez-Conde M, Fernandez I, Perello C, Gallego A, Bonacci M, Pascasio JM, et al. Effectiveness and safety of elbasvir\/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort. J Viral Hepat. 2019;26(1):55\u201364. https:\/\/doi.org\/10.1111\/jvh.13008.","journal-title":"J Viral Hepat."},{"issue":"11","key":"293_CR21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/apt.14635","volume":"47","author":"SL Flamm","year":"2018","unstructured":"Flamm SL, Bacon B, Curry MP, Milligan S, Nwankwo CU, Tsai N, et al. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther. 2018;47(11):1511\u201322. https:\/\/doi.org\/10.1111\/apt.14635.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"293_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/hep.28625","volume":"64","author":"LI Backus","year":"2016","unstructured":"Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir\/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405\u201314. https:\/\/doi.org\/10.1002\/hep.28625.","journal-title":"Hepatology"},{"issue":"5","key":"293_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/apt.14204","volume":"46","author":"MP Curry","year":"2017","unstructured":"Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017;46(5):540\u20138. https:\/\/doi.org\/10.1111\/apt.14204.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"293_CR24","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/apt.15222","volume":"49","author":"T Berg","year":"2019","unstructured":"Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther. 2019;49(8):1052\u20139. https:\/\/doi.org\/10.1111\/apt.15222.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00293-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-020-00293-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00293-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:28:51Z","timestamp":1715668131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-020-00293-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00293-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}